Newsfeeds - Spark Newswire

2 minute read

Earnings

Co-Diagnostics’s Return On Capital Employed Overview

September 30, 11:22 AM

According to Benzinga Pro, during Q2, Co-Diagnostics (NASDAQ:CODX) earned $11.79 million, a 14.09% increase from the preceding quarter. Co-Diagnostics also posted a total of $27.36 million in sales, a 36.62% increase since Q1.

CODX

1 minute read

FDA
News

Co-Diagnostics To Introduce Home/Point Of Care Device At AACC On Sept. 28

By Benzinga Newsdesk

September 27, 9:32 AM

Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be

CODX

2 minute read

News

Co-Diagnostics Announces Corporate Rebranding Following Period Of Transformative Growth And Expansion

By Benzinga Newsdesk

September 23, 9:30 AM

Co-Diagnostics, Inc.(NASDAQ:CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that following its recent

CODX

1 minute read

Co-Diagnostics Reports Its Logix Smart Flu A/B/COVID-19 Test Approved For Sale In Mexico

By Benzinga Newsdesk

September 21, 9:32 AM

Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ Influenza A/Influenza B/COVID-19

CODX

1 minute read

Events
News

Co-Diagnostics To Present At Sidoti Virtual Investor Conference Thursday, Sept. 23, 2021 At 3:15 p.m. EDT

By Benzinga Newsdesk

September 20, 5:05 PM

Co-Diagnostics, Inc. (NASDAQ:CODX) a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Dwight Egan, CEO, Brian Brown, CFO, and Andrew

CODX

2 minute read

News

A Look Into Healthcare Sector Value Stocks

By Benzinga Insights

September 13, 10:27 AM

What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

CODX

2 minute read

FDA
News

Co-Diagnostics SARS-CoV-2 Test Used In New Community Surveillance Method In Italy

By Benzinga Newsdesk

September 8, 9:35 AM

o-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ COVID-19 Test Kit was used by

CODX

4 minute read

46 Biggest Movers From Yesterday

By Lisa Levin

August 19, 5:11 AM

Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares climbed 189.5% to close at $9.90 on Wednesday after surging over 15% on Tuesday.

ABUS

6 minute read

78 Biggest Movers From Friday

By Lisa Levin

August 16, 5:12 AM

Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 43.4% to close at $3.27. PharmaCyte Biotech recently reported closing of $15-million public offering.

ABCL